¹⁷⁷Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an alternative to the more advanced ¹⁷⁷Lu-PSMA-617. The peptide is conjugated with a truncated Evans Blue (EB) molecule and DOTA chelator.

¹⁷⁷Lu-EB-PSMA-617 is explored in patients with metastatic castration resistant prostate cancer (Phase I/II). The drug has the same target population has ¹⁷⁷Lu-Vipivotide tetraxetan and must be considered as a ‘me-too’ compared to this drug.

The first Phase I study was completed during the year 2018. Patients were selected on the basis of ⁶⁸Ga-PSMA-617. The molecule showed a safety and tolerability profile similar to ¹⁷⁷Lu-Vipivotide tetraxetan.

Target/Mechanism: PSMA

Carrier/Ligand: EB-PSMA-617

Radiation Type: beta electrons (β–)